Abiraterone acetate and acute leukemia: a casual association?. Issue 1 (January 2021)

• Record Type: Journal Article
• Authors: Bolzacchini, Elena; Patriarca, Carlo; Giordano, Monica
• Is Part Of: Anti-cancer drugs. Volume 32:Issue 1(2021)
• Publication Date: 2021-01
• Subjects: abiraterone acetate -- leukemia -- prostate cancer; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000000988
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : We present the case of a 70-year-old patient affected by metastatic castration-resistant prostate cancer. He underwent radical prostatectomy in 2007 and subsequent adjuvant radiotherapy and hormonal therapy for 2 years. In 2011, he developed bilateral lung metastases, and therefore he received chemotherapy (eight cycles of docetaxel 75 mg/sqm every 3 weeks) with partial remission; rechallenge with the same drug was performed 7 months later due to recurrence of lung metastases. In August 2013, abiraterone acetate was started for progression of lung metastases. The patient received abiraterone for almost 5 years with stability of disease. During the 60th cycle of abiraterone, a diagnosis of acute myeloid leukemia was made. Abstract : Supplemental Digital Content is available in the text.